热门资讯> 正文

Vaxcyte定价13亿美元股权发行

2024-09-05 14:37

Vaxcyte(PCVX) 0
辉瑞(PFE) 0

Clinical-stage vaccine innovation company Vaxcyte (NASDAQ:PCVX) priced of an underwritten public offering of ~10.19M shares and pre-funded warrants to purchase ~2.43M shares.
The shares of common stock are being sold at a public offering price of $103.00 per share.
Gross proceeds are expected to be ~$1.3B.
The offering is expected to close on September 6, 2024.

More on Vaxcyte

Biggest stock movers today: U, BA, X, and more
Vaxcyte pneumococcal shot matches Pfizer’s in early trial for safety
Seeking Alpha’s Quant Rating on Vaxcyte
Historical earnings data for Vaxcyte
Financial information for Vaxcyte

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。